On Thursday, Uganda confirmed an outbreak of the Ebola virus in its capital city Kampala, with the first confirmed patient dying from it a day before. As per the new developments, the officials are now preparing to deploy a trial vaccine to put an end to this outbreak.
Groups of scientists are working on the vaccine and deployment of more than 2,000 doses of a candidate vaccine against the Sudan strain of Ebola has been planned and confirmed by the Uganda Virus Research Institute. As per the World Health Organization (WHO), Uganda has access to 2,169 doses of trial vaccine. For now, however, there are no approved vaccines for the strain and officials are still investigating the source of the outbreak.
The WHO had also allocated $1 million from its contingency fund for emergencies to support quick action and contain the outbreak in the country.
On Wednesday, the Sudan strain of Ebola killed a nurse employed at Kampala's main referral hospital. It is after his death that Ebola was declared an outbreak in the country. Post-mortem samples too have confirmed the Sudan Ebola Virus Disease and at least 44 contacts of the deceased man have been listed for tracing. 30 of these are health workers.
Ebola is a highly infectious hemorrhagic fever, which is transmitted through contact with bodily fluids and tissue. Symptoms include headache, vomiting of blood, muscle pains and bleeding.
it was in the late 2022, when Uganda had last suffered an Ebola outbreak. It killed 55 of the 143 people who were infected and was declared over on January 11, 2023.
As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal. People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person such as saliva, urine, faeces or semen, or things that have body fluids of an infected person like clothes or sheets.
Ebola enters the body through cuts in the skin or when one is touching their eyes, nose or mouth. Early symptoms include fever, fatigue and headache.
It was first discovered in 1976 in two simultaneous outbreak, when in Nzara, South Sudan and other in Yambuku, Democratic Republic of Congo. The latter occurred near a village near the Ebola River, which is where it gets its name from.
It is highly infectious and transmissible disease, in fact, there have been cases of health-care workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.
Cases of people conducted burial ceremonies, involving direct contact with the body of the deceased too can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk, or in pregnancy related fluids and tissues.
Credit: AI generated image
The World Health Organization (WHO) said on May 3 that three people who died aboard a cruise ship in the Atlantic Ocean were suspected to have been infected with hantavirus. The rodent-borne virus can cause severe and sometimes fatal respiratory illness.
"To date, one case of hantavirus infection has been laboratory confirmed, and there are five additional suspected cases," the organization said in a post on social media platform X.
"Of the six affected individuals, three have died, and one is currently in intensive care in South Africa," it added.
In a statement provided to USA TODAY, Netherlands-based expedition cruise operator Oceanwide Expeditions said it was addressing a "serious medical situation" on board m/v Hondius. The ship was en route from Argentina to Cape Verde, an island nation off Africa's west coast.
According to the Centers for Disease Control and Prevention (CDC), hantaviruses are a family of viruses that can cause severe illnesses and even death. The hantavirus is primarily spread by rodents through
The CDC notes that hantaviruses are capable of causing diseases like hantavirus pulmonary syndrome or HPS and hemorrhagic fever with renal syndrome or HERS.
It can infect and cause serious diseases in people. It has mainly two syndromes. One is found in the Western Hemisphere, including in the US, which can cause HPS.
The most common hantavirus that causes HPS in the US is spread by the deer mouse. HERS is a group that is similar to illnesses caused by hantaviruses and is found mostly in Asia and Europe. There's another type, called the Seoul virus, which is a type of hantavirus that causes HERS and is found worldwide, including in the US.
The WHO did not specify the type of hantavirus or syndrome in the cruise incident, but did mention respiratory risks.
According to the CDC, symptoms can appear one to eight weeks after exposure, initially presenting fatigue, fever, and muscle aches. As the disease progresses, it can cause coughing, shortness of breath, and chest tightness as fluid accumulates in the lungs.
The CDC reports that about one-third of individuals who develop respiratory symptoms from the disease may not survive.
Despite extensive research, many questions remain unanswered, including why some cases are mild while others become severe and how antibodies develop. She and other researchers have been tracking patients over extended periods, hoping to uncover potential treatments.
Also read: India Concerned Over Measles Outbreak, Action Underway: Dr N K Arora| Exclusive
You can reduce your risk by eliminating and minimizing your contact with rodents in your home, workplace, or campsite. The best way is to seal holes and gaps in your home or garage and keep the rodents from entering your home. You can also place traps in and around your home to decrease rodent infestation. Clean up any easy-to-get food that could attract rodents.
CDC notes that the diagnosis in a person who has been infected for less than 72 hours is difficult. If the initial test is done before the virus can be found, then a repeat test is required after 72 hours whenever the symptoms start to show up. Early symptoms, as mentioned above, like fever, headache, muscle aches, nausea, and fatigue, could also be easily confused with influenza, thus a test is extremely important.
Credit: AI generated image
The US has witnessed 50 large tuberculosis outbreaks (defined as 10 or more related cases in three years) across 23 states from 2017 through 2023, according to a new report by the Centers for Disease Control and Prevention.
The latest Morbidity and Mortality Weekly Report showed that the numbers, primarily involving U.S.-born persons, have more than doubled in recent years and disproportionately affected socially and economically vulnerable populations.
The outbreaks accounted for 1,092 of the 61,993 cases reported during the period. Two-thirds of large outbreaks occurred within family and social networks. Persons with TB in large outbreaks reported substance use, homelessness, and incarceration more often than did other persons with TB.
The numbers also show a sharp increase from the 24 identified from 2014 to 2016, suggesting that transmission within family and social networks is an ongoing issue, despite the US having one of the lowest TB incidence rates in the world.
“Approximately 80 per cent of large outbreak-related cases occurred among US-born persons. The identification of large outbreaks in approximately one-half of US states, including many with TB incidence below the national average, indicates that maintaining public health capacity for TB outbreak prevention, detection, and response remains critical even in jurisdictions with low TB incidence,” said corresponding author Kala M. Raz, from the Division of Tuberculosis Elimination, CDC
Notably, the report showed that people involved in the large outbreaks differed from other TB patients. The differences include:
The CDC report calls for maintaining public health capacity for TB outbreak detection, prevention, and response, even in areas with low TB incidence.
Importantly, they pressed for national genomic surveillance to help prevent and control outbreaks at the local levels.
They also emphasize the need for targeted public health strategies focused on populations at increased risk, particularly those experiencing housing instability, substance use, or incarceration.
Tuberculosis (TB) is a bacterial infection that primarily affects the lungs but can spread to other parts of the body. It is transmitted through the air when an infected person coughs or sneezes. Without proper treatment, TB can be fatal.
What Are The Symptoms?
Persistent cough that lasts more than three weeks
Fever
Night sweats
Unexplained weight loss.
Credit: Hyperfine Inc
In a significant public health move, the All India Institute of Medical Sciences, New Delhi, has deployed India’s first portable MRI for bedside brain scans, marking an important milestone for neurological care across the country.
The MRI system, installed at the AIIMS’ Center for Neurological Conditions, will enable rapid brain imaging for critically ill patients in ICUs, emergencies, and neurosurgical care.
The ultra-low-field device can be wheeled directly to patients, eliminating the need for dedicated MRI suites or risky patient transfers.
“Bedside brain imaging transforms how we care for our most critically ill patients. At AIIMS, we manage thousands of stroke and ICU patients annually, where rapid neuroimaging is essential—yet transport to conventional MRI is often unsafe or impossible,” said Dr. Shailesh Gaikwad, Head, Department of Neuroimaging and Interventional Neuroradiology and Chief of Neuroscience Centre, AIIMS New Delhi, in a statement.
The Swoop MRI system, developed by US-based medical technology company Hyperfine, is the world's first FDA-cleared, portable, and ultra-low-field magnetic resonance brain imaging system capable of providing imaging at multiple points of care.
It is expected to improve rapid diagnosis in stroke, trauma, ICU monitoring, pediatrics, and post-operative neurosurgical care.
Across the world, portable bedside MRI systems are being used in hospitals in the US, Canada, Australia, the UK, New Zealand, and various EU countries.
“The Swoop system eliminates that barrier. Now our clinicians can obtain diagnostic images at the point of care, enabling faster decision-making in neurology, trauma, and critical care," Dr Gaikwad explained.
Also read: India’s Vaccine Initiatives: HPV For Girls, Indigenous Dengue Shot On The Horizon
He added that as AIIMS Delhi "serves as a referral center across India, this deployment signals what's possible when technology and clinical need align to advance neurological care”.
The technology enables faster decision-making in emergencies, in cases where conventional imaging is difficult or unsafe.
The installation in AIIMS Delhi follows regulatory approval in India, Hyperfine said in a statement.
Experts stated that the development could significantly expand access to brain imaging and strengthen research in point-of-care neurodiagnostics nationwide.

Conventional high-field MRI systems require dedicated shielded rooms, specialized infrastructure, and patient transport.
For critically ill patients in ICUs, trauma bays, neurosurgery wards, neonatal units, and emergency departments, transport is often not feasible. These limitations can delay diagnosis and treatment and impact outcomes.
On the other hand, the Swoop system
“Bringing the Swoop system to AIIMS New Delhi is an important milestone following regulatory approval last December. India has a significant unmet need for accessible brain imaging. Deployment at the country’s leading institution signals the start of bringing point-of-care brain MRI to sites of care and institutions across India, where it can serve clinicians and their patients across neurological conditions,” said Maria Sainz, President and CEO of Hyperfine.
The Swoop system deployment at AIIMS New Delhi also establishes a foundation for clinical research. The AIIMS New Delhi team plans to document outcomes, contribute to peer-reviewed publications, and advance India’s role in the growing global evidence base for point-of-care brain imaging.
© 2024 Bennett, Coleman & Company Limited